Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Intravenous Vitamin C
CNS Pharmaceuticals
Pancreatic Cancer
1 trial -
Iopofosine I 131
Cellectar Biosciences
Breast Cancer
1 trial -
Ipatasertib
Hoffmann-La Roche
Breast Cancer
1 trial -
Ipilimumab
Regeneron UK Limited
Stage III Prostate Cancer
1 trial -
Irinotecan Accord 20 mg/ml concentraat voor oplossing voor infusie
Disc Medicine
Gastric cancer
1 trial -
Itraconazole
United Therapeutics Europe Ltd
Non-small Cell Lung Cancer
1 trial -
JANX007
Janux Therapeutics
Prostate Cancer
1 trial -
JANX008
Janux Therapeutics
Non-Small Cell Lung Cancer
1 trial -
JANX014
Janux Therapeutics
Prostate Cancer
1 trial -
JSB462
Novartis Pharmaceuticals
Metastatic Prostate Cancer (mCRPC)
1 trial -
JZP815
Jazz Pharmaceuticals Ireland Limited
Advanced Cancer
1 trial -
KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer
Boehringer Ingelheim
G12D/G12V Pancreatic Ductal Adenocarcinoma
1 trial -
KK-LC-1 TCR-T cells
Iovance Biotherapeutics B.V.
Gastric Cancer
1 trial -
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Kura Oncology
Pancreatic Ductal Adeno Carcinoma, Colorectal Cancer, Non- Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma
1 trial -
KRAS Vaccine with Poly-ICLC adjuvant
United Therapeutics Europe Ltd
Colorectal Cancer
1 trial -
KXV01 TCR Lentinvivo Injection
The First People's Hospital of Lianyungang
Advanced Solid Cancer
1 trial -
LB1908
Nanjing Legend Biotech Co.
Gastric Cancer
1 trial -
LB2102
Nanjing Legend Biotech Co.
Small Cell Lung Cancer Extensive Stage
1 trial -
LCAR-C182A cells
Nanjing Legend Biotech Co.
Gastric Cancer
1 trial -
LCAR-M23 cells
Nanjing Legend Biotech Co.
Epithelial Ovarian Cancer
1 trial -
LEE011
Novartis Pharmaceuticals
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
1 trial -
Larotinib
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Esophageal Cancer
1 trial -
Letrozole
Context Therapeutics
Metastatic Breast Cancer
1 trial -
Locametz 25 micrograms kit for radiopharmaceutical preparation, -, Pluvicto 1 000 MBq/mL solution for injection/infusion
Novartis Pharmaceuticals
Metastatic Castration-Resistant Prostate Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources